flurazepam ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
diazepam derivatives 1218 17617-23-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • flurazepam
  • stauroderm
  • flurazepam hydrochloride
  • flurazepam HCl
A benzodiazepine derivative used mainly as a hypnotic.
  • Molecular weight: 387.88
  • Formula: C21H23ClFN3O
  • CLOGP: 4.21
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 0
  • TPSA: 35.91
  • ALOGS: -4.59
  • ROTB: 6

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
30 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 500 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.10 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 83 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
April 7, 1970 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sopor 617.33 43.72 146 2045 20776 56269100
Drug abuse 526.64 43.72 165 2026 67445 56222431
Intentional self-injury 279.64 43.72 81 2110 24911 56264965
Intentional overdose 196.59 43.72 80 2111 68037 56221839
Suicide attempt 177.38 43.72 71 2120 57765 56232111
Bradyphrenia 127.64 43.72 33 2158 6587 56283289
Toxicity to various agents 98.16 43.72 76 2115 224488 56065388
Substance abuse 74.91 43.72 20 2171 4505 56285371
Hypokinesia 50.76 43.72 19 2172 12784 56277092
Coma 44.19 43.72 28 2163 59627 56230249

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug abuse 163.04 41.56 72 997 87686 31608589
Sopor 137.11 41.56 38 1031 11514 31684761
Intentional self-injury 105.44 41.56 32 1037 13283 31682992
Psychomotor hyperactivity 60.51 41.56 19 1050 8768 31687507

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sopor 702.37 34.77 180 2967 31087 70894210
Drug abuse 618.32 34.77 234 2913 147022 70778275
Intentional self-injury 390.67 34.77 114 3033 31536 70893761
Bradyphrenia 159.24 34.77 44 3103 9902 70915395
Suicide attempt 158.61 34.77 75 3072 79435 70845862
Intentional overdose 157.91 34.77 80 3067 98355 70826942
Toxicity to various agents 81.45 34.77 92 3055 382080 70543217
Substance abuse 56.99 34.77 20 3127 9817 70915480
Hypokinesia 49.17 34.77 21 3126 17411 70907886
Psychomotor hyperactivity 48.23 34.77 20 3127 15413 70909884
Bradykinesia 46.33 34.77 16 3131 7486 70917811
Drug interaction 41.13 34.77 66 3081 381375 70543922
Coma 38.15 34.77 32 3115 91812 70833485

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05CD01 NERVOUS SYSTEM
PSYCHOLEPTICS
HYPNOTICS AND SEDATIVES
Benzodiazepine derivatives
FDA CS M0002356 Benzodiazepines
CHEBI has role CHEBI:35474 anti-anxiety agents
CHEBI has role CHEBI:35623 anticonvulsants
CHEBI has role CHEBI:35717 hypnotics
CHEBI has role CHEBI:91016 GABAA receptor agonists
MeSH PA D014151 Anti-Anxiety Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D018682 GABA Agents
MeSH PA D018757 GABA Modulators
MeSH PA D006993 Hypnotics and Sedatives
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014149 Tranquilizing Agents
FDA EPC N0000175694 Benzodiazepine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Insomnia indication 193462001
Suicidal thoughts contraindication 6471006
Disorder of lung contraindication 19829001 DOID:850
Borderline personality disorder contraindication 20010003 DOID:10930
Alcohol intoxication contraindication 25702006
Shock contraindication 27942005
Depressive disorder contraindication 35489007
Substance abuse contraindication 66214007
Psychotic disorder contraindication 69322001
Sleep apnea contraindication 73430006 DOID:0050847
Decreased respiratory function contraindication 80954004
Kidney disease contraindication 90708001 DOID:557
Hypoalbuminemia contraindication 119247004
Disease of liver contraindication 235856003 DOID:409
Sleep automatism contraindication 247962006
Pregnancy, function contraindication 289908002
Coma contraindication 371632003
Breastfeeding (mother) contraindication 413712001
Porphyria contraindication 418470004
Behavioral Disorders contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.24 Basic
pKa2 1.92 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
GABA-A receptor alpha-1/beta-2/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR IC50 8.10 WOMBAT-PK CHEMBL
Solute carrier family 22 member 2 Transporter IC50 4.22 WOMBAT-PK

External reference:

IDSource
4019763 VUID
N0000147854 NUI
D00329 KEGG_DRUG
1172-18-5 SECONDARY_CAS_RN
4017827 VANDF
4019763 VANDF
C0016375 UMLSCUI
CHEBI:5128 CHEBI
FL7 PDB_CHEM_ID
CHEMBL3989724 ChEMBL_ID
CHEMBL968 ChEMBL_ID
DB00690 DRUGBANK_ID
D005479 MESH_DESCRIPTOR_UI
3393 PUBCHEM_CID
7188 IUPHAR_LIGAND_ID
2551 INN_ID
IHP475989U UNII
4501 RXNORM
4752 MMSL
70 MMSL
d00238 MMSL
001463 NDDF
004584 NDDF
19403009 SNOMEDCT_US
27928002 SNOMEDCT_US
387109000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Flurazepam Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-4415 CAPSULE 15 mg ORAL ANDA 27 sections
Flurazepam Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-4415 CAPSULE 15 mg ORAL ANDA 27 sections
Flurazepam Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-4430 CAPSULE 30 mg ORAL ANDA 27 sections
Flurazepam Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-4430 CAPSULE 30 mg ORAL ANDA 27 sections
Flurazepam HUMAN PRESCRIPTION DRUG LABEL 1 21695-363 CAPSULE 30 mg ORAL ANDA 19 sections
Flurazepam HUMAN PRESCRIPTION DRUG LABEL 1 52959-236 CAPSULE 30 mg ORAL ANDA 19 sections
Flurazepam Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 54868-0092 CAPSULE 15 mg ORAL ANDA 14 sections
Flurazepam Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 54868-0093 CAPSULE 30 mg ORAL ANDA 14 sections
Flurazepam Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 55289-038 CAPSULE 30 mg ORAL ANDA 26 sections